

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



re Application of:

GIL-AD et al.

Serial Number: 10/774,694

Filed: February 10, 2004

For: **ANTI-PROLIFERATIVE DRUGS**

Group Art Unit: 1623

Conf. No.: 8587

Examiner: OLSON, Eric

TRANSMITTAL LETTER

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter
- (2) Information Disclosure Statement;
- (3) PTO Form 1449 citing 60 references;
- (4) 47 references attached;
- (5) Check no. 3559 \$ 180.00 for submission of IDS.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,
THE NATH LAW GROUP

By:

Gary M. Nath
 Registration No. 26,965
 Susanne M. Hopkins
 Registration No. 33,247
 Customer No. 20529

Date: January 17, 2007
THE NATH LAW GROUP
 112 South West Street
 Alexandria, VA 22314
 Phone: 703-548-6284
 Fax: 703-683-8396
 GMN/SMH/dd:IDS.TRANS



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

GIL-AD et al.

Group Art Unit: 1623

Serial Number: 10/774,694

Conf. No.: 8587

Filed: February 10, 2004

Examiner: OLSON, Eric

For: ANTI-PROLIFERATIVE DRUGS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. § 1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

- [] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [x] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

The enclosed statement is accompanied by [check one]:

- [] i. a certification in part (e) below as specified in 37 C.F.R. § 1.97(e), or
- [x] ii. a check in the amount required by 37 C.F.R. § 1.17(p).
- [] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, but before payment of the issue fee.
 - [] Certification report(e) below; and
 - [] a check in the amount as required by § 1.17(p).
- [] d. The enclosed statement is being filed pursuant to 37 C.F.R. § 1.97(i), for placement in the file.
- [] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

[] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

And/or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

or Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.


Respectfully submitted,
THE NATH LAW GROUP

By:



Gary M. Nath
Registration No. 26,965
Susanne M. Hopkins
Registration No. 33,247
Customer No. 20529

Date: January 17, 2007
THE NATH LAW GROUP
112 South West Street
Alexandria, VA 22314
Phone: 703-548-6284
Fax: 703-683-8396
GMN/SMH/dd (IDS.revisedNov03)



FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Atty Docket 25464X	Serial No. 10/774,694
-----------------------	--------------------------

Applicant GIL-AD et al.

Filing Date February 10, 2004	Group Art Unit 1623
----------------------------------	------------------------

U. S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA	5,789,339	25 Aug 1998	Brandes			28 Jun 1993
	AB	5,795,895	18 Aug 1998	Anchors			13 Jun 1997
	AC	5,639,950	17 Jun 1997	Verma, et al.			29 Jun 1994
	AD	4,018,985	19 Apr 1977	Molloy, et al.			17 Sep 1975
	AE	4,314,081	2 Feb 1982	Molloy, et al.			10 Jan 1974
	AF	5,110,802	5 May 1992	Cantin, et al.			14 Jul 1987
	AG	5,166,437	24 Nov 1992	Kairisalo, et al.			23 Nov 1990
	AH	5,194,428	16 Mar 1993	Agrawal, et al.			30 Apr 1990
	AI	5,216,141	1 Jun 1993	Benner			6 Jun 1988
	AJ	5,776,925	7 Jul 1998	Young, et al.			25 Jan 1996
	AK	5,859,065	12 Jan 1999	Brandes			1 Aug 1997
	AL	6,258,853	10 Jul 2001	Stowell, et al.			31 Jan 2001

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Translation
	AM	WO 94/18961 A1	1 Sep 1994	WIPO			N/A
	AN	WO 92/11035 A1	9 Jul 1992	WIPO			N/A
	AO	WO 02/43652 A2	6 Jun 2002	WIPO			N/A
	AP	WO 99/24415 A1	20 May 1999	WIPO			abstract
	AQ	WO 99/25344 A1	27 May 1999	WIPO			N/A

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR		Abdul, M., et al., "Growth-Inhibitory Effects of Serotonin Uptake Inhibitors on Human Prostate Carcinoma Cell Lines", <u>The Journal of Urology</u> , Vol. 154, Pg. 247-250, (1995).
AS		Bachmeier, B. E., et al., "Human Keratinocyte Cell Lines Differ in the Expression of the Collagenolytic Matrix Metalloproteinases-1, -8, and -13 and of TIMP-1", <u>Biol. Chem.</u> Vol. 381, Pg. 509-516, (2000).
AT		Bradley, D. J., et al., "Elicitor- and Wound-Induced Oxidative Cross-Linking of a Proline-Rich Plant Cell Wall Protein: A Novel, Rapid Defense Response", <u>Cell</u> , Vol. 70, Pg. 21-30, (1992).

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE
CITATION

Inventor: GIL-AD, et al.

Art Unit: 1623

Appl. No.: 10/774,694

Examiner: unknown

Filing Date:

February 10, 2004

U.S. PATENT DOCUMENTS

Exam. Initial	Document No.	Issue/Public. Date	Inventor	Filed Date
AU	6,024,977	15 Feb 2000	Yatvin, et al.	3 Sep 1997
AV				
AW				
AX				
AY				
AZ				
AAA				
AAB				
AAC				
AAD				
AAE				
AAF				

FOREIGN PATENT DOCUMENTS

Exam. Initial	Document No.	Public. Date	Country	Translation
AAG	681780 A5	28 May 1993	CH	NO
AAH	WO 01/80896 A2	1 Nov 2001	WIPO	N/A
AAI	WO 94/18961 A1	1 Sep 1994	WIPO	N/A
AAJ	2660194	4 Oct 1991	FR	NO

OTHER

Exam. Initial	(Including Author, Title, Date, Pertinent Pages, etc.)	
	AAK	Brandes, L. J., et al., "Stimulation of Malignant Growth in Rodents by Antidepressant Drugs at Clinically Relevant Doses", <u>Cancer Research</u> , Vol. 52, Pg. 3796-3800, (1992).
	AAL	Calabresi, P., et al., "Chemotherapy of Neoplastic Diseases", <u>The Pharmacological Basis of Therapeutics</u> , Section XII, Pg. 1202-1263, (1990).
	AAM	Cookson, J., et al., "Fluoxetine: therapeutic and undesirable effects", <u>Hospital Medicine</u> , Vol. 59, No. 8, Pg. 622-626, (1998).
	AAN	Cotterchio, M., et al., "Antidepressant Medication Use and Breast Cancer Risk", <u>American Journal of Epidemiology</u> , Vol. 151, No. 10, Pg. 951-957, (2000).
	AAO	Dalton, W. S., "Reversing Multidrug-Resistance in the Laboratory and Clinic", <u>Proceedings of the American Association for Cancer Research</u> , Vol. 31, Pg. 520-521, (1990).
	AAP	DeVita, Jr., V. T., et al., "Cancer, Principles & Practice of Oncology", Vol. 2, 4 th Ed., Pg. 2661-2664, (1993).
	AAQ	Deutch, C. E., et al., "Post-transcriptional regulation of a salt-inducible alfalfa gene encoding a putative chimeric praline-rich cell wall protein", <u>Plant Molecular Biology</u> , Vol. 27, Pg. 411-418, (1995).
	AAR	Esaka, M., et al., "Specific Secretion of Proline-Rich Proteins by Salt-Adapted Winged Bean Cells", <u>Plant Cell Physiol.</u> , Vol. 36, No. 3, Pg. 441-446, (1995).
	AAS	Galil, S., et al., "Enhanced levels of free and protein-bound threonine in transgenic alfalfa (<i>Medicago sativa</i> L.) expressing a bacterial feedback-insensitive aspartate kinase gene", <u>Transgenic Research</u> , Vol. 9, pp 137-144, (2000)

	AAT	Goodwin, W., et al., "Transcripts of a gene encoding a putative cell wall-plasma membrane linker protein are specifically cold-induced in <i>Brassica napus</i> ", <u>Plant Molecular Biolgy</u> , Vol. 31, Pg. 771-781, (1996).
	AAU	Gupta, M. A., et al., "Psychotropic drugs in dermatology", <u>J Am Acad Dermatol</u> , Vol. 14, No. 4, Pg. 633-645, (April 1986).
	AAV	Hare, P. D., et al., "Metabolic implications of stress-induced praline accumulation in plants", <u>Plant Growth Regulation</u> , Vol. 21, Pg. 79-102, (1997).
	AAW	Hemlock, C., et al., "Fluoxetine-induced Psoriasis", <u>The Annals of Pharmacotherapy</u> , Vol. 26, Pg. 211-212, (February 1992).
	AAX	Johnson, R. K., et al., "In Vivo Characteristics of Resistance and Cross-Resistance of an Adriamycin-Resistant Subline of P388 Leukemia", <u>Cancer Treatment Rep.</u> , Vol. 62, No. 10 Pg. 1535-1547, (1978).
	AAY	Karchi, H., et al., "Lysine synthesis and catabolism are coordinately regulated during tobacco seed development", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 91, Pg. 2577-2581, (March 1994).
	AAZ	Kaye, C., et al., "Characterization of a Gene for Spinach CAP160 and Expression of Two Spinach Cold-Acclimation Proteins in Tobacco", <u>Plant Physiol.</u> , Vol. 116, Pg. 1367-1377, (1998).
	AAAA	Memelink, J., et al., "Structure and regulation of tobacco extensin", <u>The Plant Journal</u> , Vol. 4, No. 6, Pg. 1011-1022, (1993).
	AAAB	Nanjo, T., et al., "Antisense suppression of praline degradation improves tolerance to freezing and salinity in <i>Arabidopsis thaliana</i> ", <u>FEBS Letters</u> , Vol. 461, Pg. 205-210, (1999).
	AAAC	Nordenberg, J., et al., "Effects of Psychotropic Drugs on Cell Proliferation and Differentiation", <u>Biochemical Pharmacology</u> , Vol. 58, Pg. 1229-1236, (1999).
	AAAD	Sonneveld, P., et al., "Inhibitors of multidrug resistance", <u>Curr. Opin. Oncol.</u> , Vol. 9, No. 6, Pg. 543-548, (1997).
	AAAE	Strobl, J. S., et al., "The cell death response to γ -radiation in MCF-7 cells is enhanced by a neuroleptic drug, pimozide", <u>Breast Cancer Research and Treatment</u> , Vol. 51, Pg. 83-95, (1998).
	AAAF	Szoke, A., et al., "Subcellular Location of Δ^1 -Pyrroline-5-Carboxylate Reductase in Root/Nodule and Leaf of Soybean ¹ ", <u>Plant Physiol.</u> , Vol. 99, Pg. 1642-1649, (1992).
	AAAG	Tan, B., et al., "Multidrug resistance transporters and modulation", <u>Current Opinion in Oncology</u> , Vol. 12, Pg. 450-458, (2000).
	AAAH	Tennyson, H., et al., "Neurotropic and Psychotropic Drugs in Dermatology", <u>Systemic Dermatologic Therapy</u> , Vol. 19, No. 1, Pg. 179-197, (January 2001).
	AAAI	Vindelov, L. L., et al., "A Detergent-Trypsin Method for the Preparation of Nuclei for Flow Cytometric DNA Analysis", <u>Cytometry</u> , Vol. 3, No. 5, Pg. 323-327, (1983).
	AAAJ	Wang, P. S., et al., "Antidepressant use and the risk of breast cancer: A non-association", <u>Journal of Clinical Epidemiology</u> , Vol. 54, Pg. 728-734, (2001).
	AAAK	Xia, Z., et al., "The Antidepressants Imipramine, Clomipramine, and Citalopram Induce Apoptosis in Human Acute Myeloid Leukemia HL-60 Cells via Caspase-3 Activation", <u>J Biochem Molecular Toxicology</u> , Vol. 13, No. 6, Pg. 338-347, (1999).

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Page 4 of 4